Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDX-010 in B-cell Non-Hodgkin's Lymphoma
NCT00089076Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Jun 2004
- Primary completion
- Jul 2008
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ipilimumab in B-cell non-Hodgkin lymphoma (B-NHL), sponsored by National Cancer Institute. Started Jun 2004; status: terminated.
02
Drugs
ipilimumab
03
Conditions
B-cell non-Hodgkin lymphoma (B-NHL)
Beyond the preview
Go deeper on NCT00089076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00089076.